These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16015504)

  • 1. Decitabine in acute myeloid leukemia.
    Lübbert M; Minden M
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S38-42. PubMed ID: 16015504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decitabine in myelodysplastic syndromes.
    Saba HI; Wijermans PW
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
    Wijermans PW; Lübbert M; Verhoef G; Klimek V; Bosly A
    Ann Hematol; 2005 Dec; 84 Suppl 1():9-17. PubMed ID: 16211386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
    Quintás-Cardama A; Ravandi F; Liu-Dumlao T; Brandt M; Faderl S; Pierce S; Borthakur G; Garcia-Manero G; Cortes J; Kantarjian H
    Blood; 2012 Dec; 120(24):4840-5. PubMed ID: 23071272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine.
    Hackanson B; Daskalakis M
    Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decitabine in chronic leukemias.
    Issa JP; Byrd JC
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S43-9. PubMed ID: 16015505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine.
    Daskalakis M; Blagitko-Dorfs N; Hackanson B
    Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine: a historical review of the development of an epigenetic drug.
    de Vos D; van Overveld W
    Ann Hematol; 2005 Dec; 84 Suppl 1(Suppl 1):3-8. PubMed ID: 16220311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methyltransferases as targets for cancer therapy.
    Ghoshal K; Bai S
    Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
    Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
    Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
    Fenaux P
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demethylating agents in myeloid malignancies.
    Garcia-Manero G
    Curr Opin Oncol; 2008 Nov; 20(6):705-10. PubMed ID: 18841054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
    Issa JP; Garcia-Manero G; Giles FJ; Mannari R; Thomas D; Faderl S; Bayar E; Lyons J; Rosenfeld CS; Cortes J; Kantarjian HM
    Blood; 2004 Mar; 103(5):1635-40. PubMed ID: 14604977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
    Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
    Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of decitabine for the treatment of acute myeloid leukemia.
    Ganetsky A
    Ann Pharmacother; 2012 Nov; 46(11):1511-7. PubMed ID: 23115225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.
    Jabbour E; Garcia-Manero G; Cornelison AM; Cortes JE; Ravandi F; Daver N; Kadia T; Teng A; Kantarjian H
    Leuk Lymphoma; 2015 Feb; 56(2):390-4. PubMed ID: 24844364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.